Bavunalimab
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer[1].
Product Specifications
CAS Number
2329669-78-3
Product Name Alternative
Anti-Human CTLA4xLAG3; XmAb-22841
UNSPSC
12352203
Target
LAG-3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bavunalimab.html
Purity
99.408
Solubility
H2O
Smiles
[Bavunalimab]
Molecular Weight
(125.327 kDa)
References & Citations
[1]Perez-Santos M, et, al. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov. 2022 Nov 24;1-15.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC043527-500 1x 500 µL
CD31 / PECAM-1 (Endothelial Cell Marker) (PECAM1/3527), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
